Literature DB >> 15497674

Novel approaches to vaccine delivery.

Derek T O'Hagan1, Rino Rappuoli.   

Abstract

Although the currently available vaccines represent an outstanding success story in modern medicine and have had a dramatic effect on morbidity and mortality worldwide, it is clear that improvements are required in the current vaccine delivery technologies. Improvements are required to enable the successful development of vaccines against infectious diseases that have so far proven difficult to control with conventional approaches. Improvements may include the addition of novel injectable adjuvants or the use of novel routes of delivery, including mucosal immunization. Mucosal delivery may be required to provide protection against pathogens that infect at mucosal sites, including sexually transmitted diseases. Alternatively, novel approaches to delivery, including mucosal administration, may be used to improve compliance for existing vaccines. Of particular interest for safer mass immunization campaigns are needle-free delivery devices, which would avoid problems due to needle re-use in many parts of the world and would avoid needle-stick injuries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15497674      PMCID: PMC7088827          DOI: 10.1023/b:pham.0000041443.17935.33

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  95 in total

Review 1.  Microparticles as vaccine adjuvants and delivery systems.

Authors:  Derek T O'Hagan; Manmohan Singh
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

2.  Skin immunization made possible by cholera toxin.

Authors:  G M Glenn; M Rao; G R Matyas; C R Alving
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

3.  Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen.

Authors:  S L Jain; K S Barone; M P Flanagan; J G Michael
Journal:  Vaccine       Date:  1996-09       Impact factor: 3.641

4.  A month-long effect from a single injection of microencapsulated human growth hormone.

Authors:  O L Johnson; J L Cleland; H J Lee; M Charnis; E Duenas; W Jaworowicz; D Shepard; A Shahzamani; A J Jones; S D Putney
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

5.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

6.  Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.

Authors:  V F Vidal; N Castéran; C J Riendeau; H Kornfeld; E C Darcissac; A Capron; G M Bahr
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

7.  Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.

Authors:  Yuh-Fun Maa; Lu Zhao; Lendon G Payne; Dexiang Chen
Journal:  J Pharm Sci       Date:  2003-02       Impact factor: 3.534

8.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; T R Tice; R M Gilley
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

9.  Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles.

Authors:  B C Baudner; O Balland; M M Giuliani; P Von Hoegen; R Rappuoli; D Betbeder; G Del Giudice
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.

Authors:  T Scharton-Kersten; J m Yu; R Vassell; D O'Hagan; C R Alving; G M Glenn
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

View more
  35 in total

1.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

Review 2.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

3.  Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.

Authors:  Ahmad M Abdul-Fattah; Vu Truong-Le; Luisa Yee; Emilie Pan; Yi Ao; Devendra S Kalonia; Michael J Pikal
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

Review 4.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

5.  Preparation and Characterization of Magnetic Nano-in-Microparticles for Pulmonary Delivery.

Authors:  Amber A McBride; Dominique N Price; Pavan Muttil
Journal:  Methods Mol Biol       Date:  2017

6.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

7.  Novel antigen delivery technologies: a review.

Authors:  Deepika Jain; Vikas Jain; Ranjit Singh
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

Review 8.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

9.  Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.

Authors:  Brittany A Bailey; Kashappa-Goud H Desai; Lukasz J Ochyl; Susan M Ciotti; James J Moon; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2017-08-22       Impact factor: 4.939

Review 10.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.